Baird Maintains Outperform on Instil Bio, Raises Price Target to $180
Benzinga Newsdesk 2 years ago
NewsPrice TargetAnalyst Ratings
Baird analyst Jack Allen maintains Instil Bio (NASDAQ:TIL) with a Outperform and raises the price target from $32 to $180.
Baird analyst Jack Allen maintains Instil Bio (NASDAQ:TIL) with a Outperform and raises the price target from $32 to $180.